Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Chowdhury

Showing results (101-110 of 151) with videos related to

Pageof 16
Sort By:
Nature Medicine|May 4, 2021
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Danielle Carroll, Simon Chowdhury, et al.
Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.
The New England Journal of Medicine|June 1, 2019
Apalutamide for Metastatic, Castration-Sensitive Prostate CancerKim N Chi, Neeraj Agarwal, Anders Bjartell, et al.
Cancer|April 16, 2015
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancerMatthew D Galsky, Sumanta K Pal, Simon Chowdhury, et al.
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
JAMA Network Open|August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN TrialsSoumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate CancerCora Sternberg, Andrew Armstrong, Roberto Pili, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder CancerTracy L Rose, Allison M Deal, Sylvain Ladoire, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2021
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN StudyKim N Chi, Simon Chowdhury, Anders Bjartell, et al.
European Urology|January 19, 2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT TrialRobert J Motzer, Paul Russo, Naomi Haas, et al.
Pageof 16

Showing results (101-110 of 151) with videos related to

Sort By:
Pageof 16
Nature Medicine|May 4, 2021
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Danielle Carroll, Simon Chowdhury, et al.
Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.
The New England Journal of Medicine|June 1, 2019
Apalutamide for Metastatic, Castration-Sensitive Prostate CancerKim N Chi, Neeraj Agarwal, Anders Bjartell, et al.
Cancer|April 16, 2015
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancerMatthew D Galsky, Sumanta K Pal, Simon Chowdhury, et al.
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
JAMA Network Open|August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN TrialsSoumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate CancerCora Sternberg, Andrew Armstrong, Roberto Pili, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder CancerTracy L Rose, Allison M Deal, Sylvain Ladoire, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2021
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN StudyKim N Chi, Simon Chowdhury, Anders Bjartell, et al.
European Urology|January 19, 2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT TrialRobert J Motzer, Paul Russo, Naomi Haas, et al.
Pageof 16